Lyell completes LYL273 manufacturing transfer, pushes back Phase 1/2 data timelineSep 10Clinical readoutLyell Immunopharma, Inc.
FDA accepts BLA for Alvotech's AVT80, a subcutaneous Entyvio biosimilar candidateAug 31PartnershipAlvotechvedolizumab
Odyssey Therapeutics reports Q2 2026 results, plans next OD-001 trials in second half of 2026Aug 4Quarterly updateOdyssey Therapeutics
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin
Sign inSign in